Emerging Diagnostic Markers in Alzheimer’s DiseaseDecision ResourcesJune 14, 2005 26 Pages - SKU: DECR1186955 |
| Currently, Alzheimer's disease (AD) is diagnosed based on patient clinical history and exclusion of other neurological disorders. Because early signs of AD are hard to distinguish from normal signs of aging, most patients are not diagnosed until neuronal damage is extensive. A diagnostic marker would enable physicians to diagnose more AD patients earlier and begin drug treatment when it could be most effective. The AD therapeutics market would also benefit: early diagnosis and treatment translates to more therapy sales over longer treatment periods. In this report, we review AD diagnostic markers currently in use and in development, the main players in the AD diagnostics arena, and the impact that these markers will have on the U.S. AD market over the next ten years.
Please note: the PDF e-mail from publisher version of this report is for a global site license. |
Related Markets
Alzheimer's Disease Reports
- Alzheimer's Disease Global Clinical Trials Review, H2, 2011
- Prescribing Influences: Alzheimer's Disease - Alleviating symptoms remains the goal for prescribers
- Advances in Alzheimer's Disease Drug Discovery
- The Neurotechnology Industry 2011 Report
- The 10th International Conference on Alzheimer's and Parkinson's Diseases: Post-Conference Review and Analysis
